"10.1371_journal.pone.0141164","plos one","2015-10-21T00:00:00Z","Isabelle Poizot-Martin; Alissa Naqvi; Véronique Obry-Roguet; Marc-Antoine Valantin; Lise Cuzin; Eric Billaud; Antoine Cheret; David Rey; Christine Jacomet; Claudine Duvivier; Pascal Pugliese; Pierre Pradat; Laurent Cotte; Hepadat'AIDS Study Group","Aix-Marseille University, APHM Hôpital Sainte-Marguerite, Immuno-Hematology Clinic, Marseille, France; Inserm U912 (SESSTIM), Marseille, France; CHU de Nice, Hôpital Archet 1, Service de Maladies Infectieuses, Unité de Virologie Clinique, Nice, France; Sorbonne Universités, UPMC Université Paris 06, UMR_S 1136, Institut Pierre Louis dEpidémiologie et de Santé Publique, F-75013, Paris, France; APHP, Groupe hospitalier Pitié-Salpêtrière-Université Pierre et Marie Curie, Service de Maladies Infectieuses et Tropicales, Paris, France; INSERM, UMR 1027, Toulouse, F-31000, France; Université de Toulouse III, Toulouse, F-31000, France; CHU Toulouse, COREVIH Toulouse, F-31000, France; Service des maladies infectieuses, CHU, Hôtel-Dieu, Nantes, France; Centre Hospitalier de Tourcoing, Service Universitaire de Maladies Infectieuses, Tourcoing, France; CHU Bicêtre, Service de Médecine Interne, Le Kremlin-Bicêtre, France; Laboratoire de Virologie, Hôpital Necker EA 7327 Université Paris Descartes, Paris, France; Hôpitaux Universitaires de Strasbourg, Center for HIV care, Strasbourg, France; CHU Clermont-Ferrand, Service des Maladies Infectieuses et tropicales, Clermont-Ferrand, France; APHP-Hopital Necker, Service de Maladies Infectieuses et Tropicales, Centre dInfectiologie Necker-Pasteur IHU Imagine, Paris, France; Institut Pasteur, Centre Médical—Centre dInfectiologie Necker-Pasteur, Paris, France; Hospices civils de Lyon, Hôpital de la Croix Rousse, Service dHépatologie, Centre de recherche clinique, Lyon, France; Inserm U1052, Lyon, France; Hospices civils de Lyon, Hôpital de la Croix Rousse, Service des maladies infectieuses, Lyon, France","Conceived and designed the experiments: LCo IPM. Performed the experiments: PPu. Analyzed the data: VOR PPr LCo. Wrote the paper: IPM AN VOR MAV LCu EB AC DR CJ CD PPu PPr LCo.","Isabelle POIZOT-MARTIN is member of advisory boards for GILEAD, BMS, and ABVIE. She received speaker fees from Gilead, MSD, and BMS, and travel/accommodation grants from BMS. Marc- Antoine VALANTIN has received honoraria for consulting/educational lectures and travel grants from Janssen-Cilag, Gilead Science, ViiV Healthcare, Bristol-Myers Squibb, and Merck/Schering-Plough. Lise CUZIN participated in advisory board meetings for BMS, ViiV Healthcare and received travel grants from BMS and MSD. Eric BILLAUD received travel grants from ViiV Healthcare, Janssen, Gilead, Merck, and BMS, and expertise fees from Gilead and BMS. He also participated in advisory board meetings for MSD. David REY is member of advisory board for Gilead, received speaker fees from MSD and travel grants from Gilead, BMS, and MSD. Christine JACOMET reports grants and nonfinancial support from MSD, non-financial support from ViiV, grants from Roche, grants, personal fees and non-financial support from Janssen, personal fees from Gilead, personal fees from BMS, personal fees from Mylan, personal fees and non-financial support from Abbott, outside the submitted work. Claudine DUVIVIER has received travel grants, honoraria or study grants from various pharmaceutical companies, including Bristol- Myers-Squibb, Gilead Sciences, Janssen, Merck and ViiV Healthcare. Pascal PUGLIESE is member of advisory boards for Gilead and BMS. Laurent COTTE has received research grants from ViiV healthcare and MSD, personal fees from Mylan and non-financial support from BMS, Gilead Science, Janssen Cilag, MSD and ViiV healthcare. Alissa NAQVI, Véronique OBRY-ROGUET, Antoine CHERET, and Pierre PRADAT have no conflict of interest to disclose. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","10","Isabelle Poizot-Martin","IPM",14,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
